AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.7 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Cerebrovascular disorders in patients with malignant tumors

Ozal BeylerliaRustam TalybovbElmar MusaevcTatyana TrofimovadHuaizhang Shie( )Tatiana IlyasovafValentin Pavlovg
Central Research Laboratory, Bashkir State Medical University, Ufa, Republic of Bashkortostan, 3 Lenin Street, 450008, Russia
Department of Oncology, Radiology and Radiotherapy, Tyumen State Medical University, 54 Odesskaya Street, 625023 Tyumen, Russia
Department of Oncology, Sechenov First Moscow State Medical University, Moscow, Russia
Department of Radiology, The Pavlov First Saint Petersburg State Medical University, L’va Tolstogo Str. 6/8, St. Petersburg, 197022, Russia
Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Department of Internal Diseases, Bashkir State Medical University, Ufa, Republic of Bashkortostan 450008, Russia
Department of Urology, Bashkir State Medical University, Ufa, 3 Lenin Street, 450008, Russia
Show Author Information

Abstract

Patients with malignant tumors face an elevated risk of cerebrovascular complications, such as intratumoral hemorrhage, tumor invasion into arterial and venous sinuses, leptomeningeal infiltration, and tumor embolism. This review examines the significant role and implications of cisplatin and radiation therapy in the development of these cerebrovascular complications, which can occur at various stages: before, during, or long after the completion of cancer treatment. Detailed clinical case studies of CNS involvement during oncological therapy are presented to illustrate these complications. The mechanisms by which cisplatin and radiation therapy contribute to cerebrovascular disorders are multifaceted. Cisplatin, a widely used chemotherapeutic agent, is associated with endothelial damage and thromboembolic events, while radiation therapy can cause vascular injury, leading to long-term changes in cerebral vasculature. These treatments, though effective in managing malignancies, pose significant risks to cerebrovascular health. The review underscores the diverse types and mechanisms of stroke encountered in cancer patients, influenced by tumor stage and pathological characteristics. These include ischemic stroke, hemorrhagic stroke, and transient ischemic attacks, each requiring specific diagnostic and therapeutic strategies. The interaction between cancer pathology and cerebrovascular health necessitates a multidisciplinary approach, integrating oncology, neurology, radiology, and vascular surgery. Such an approach is crucial for effective management and prognosis evaluation in this patient population. Early recognition and intervention are paramount to mitigating risks and improving outcomes. By understanding these complex interactions, healthcare providers can better anticipate and manage cerebrovascular risks in patients undergoing cancer treatment. This comprehensive understanding helps in formulating personalized treatment plans, optimizing both oncological and neurological care, and ultimately enhancing patient quality of life and survival rates.

References

【1】
【1】
 
 
Brain Hemorrhages
Pages 284-292

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Beylerli O, Talybov R, Musaev E, et al. Cerebrovascular disorders in patients with malignant tumors. Brain Hemorrhages, 2024, 5(6): 284-292. https://doi.org/10.1016/j.hest.2024.08.003

1

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 04 July 2024
Revised: 14 August 2024
Accepted: 26 August 2024
Published: 28 August 2024
© 2024 International Hemorrhagic Stroke Association.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).